Systematic Evaluation on Olmesartan Medoxomil Pharmacoeconomics Studies
10.6039/j.issn.1001-0408.2016.08.03
- VernacularTitle:奥美沙坦酯药物经济学研究的系统评价
- Author:
Zhenxing FAN
;
Xiaoping XIE
- Publication Type:Journal Article
- Keywords:
Olmesartan medoxomil;
Pharmacoeconomics;
Systematic evaluation
- From:
China Pharmacy
2016;27(8):1017-1019
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate the pharmacoeconomics characteristic of olmesartan medoxomil in ARB anti-hypertension drugs,and to provide reference for clinical drug use. METHODS:The literatures on the pharmacoeconomics study of olmesartan medoxomil published from Jan. 2002 to Dec. 2013 were searched with assigned search strategy from domestic and international data-bases like CNKI,PubMed,etc.,and comprehensive comparison and consistency analysis were conducted. RESULTS:4 literatures about pharmacoeconomics study of olmesartan medoxomil in different countries were screened,with essential hypertension patients as target population cost-minimization analysis or cost-effectiveness analysis as method,and 9 months-5 years as study course. The results consistency was well and showed the treatment cost of olmesartan medoxomil was usually less or better cost-effectiveness. CONCLUSIONS:Olmesartan medoxomil shows pharmacoeconomics advantage among ARBs drugs based on existed literature re-view.
